Significant Accounting Policies and Concentrations of Risk Textual (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 17, 2023
Significant Accounting Policies and Concentrations of Risk [Line Items]
Restricted cash	$ 1,804,000	$ 1,472,000
Long-term investment maturity, minimum (in months)	12 months
Advertising expense	$ 14,404,000	$ 14,891,000	$ 5,705,000
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	47,539,000	56,290,000
Reclassification from accumulated other comprehensive income, current period, before tax	$ 0	$ 0	$ 1,000
Computer Equipment
Significant Accounting Policies and Concentrations of Risk [Line Items]
Property, plant and equipment, useful life (in years)	3 years
Laboratory Equipment, Office Equipment and Software
Significant Accounting Policies and Concentrations of Risk [Line Items]
Property, plant and equipment, useful life (in years)	5 years
Furniture and fixtures
Significant Accounting Policies and Concentrations of Risk [Line Items]
Property, plant and equipment, useful life (in years)	7 years
Royalty Receivable
Significant Accounting Policies and Concentrations of Risk [Line Items]
Restricted cash	$ 1,804,000	1,472,000
Collateral for Credit
Significant Accounting Policies and Concentrations of Risk [Line Items]
Restricted cash	$ 1,493,000	$ 1,449,000
Maximum
Significant Accounting Policies and Concentrations of Risk [Line Items]
Maturity period of high quality marketable securities (in years)	3 years
Average maturity period of high quality marketable securities (in months)	12 months
Maturity period of short term investment (in months)	12 months
Pharmakon Advisors, LP | Term Loan Tranche A | Line of Credit
Significant Accounting Policies and Concentrations of Risk [Line Items]
Interest expense, debt, total	$ 27,326,000
Debt instrument, face amount				$ 300,000,000